Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1987 Oct;80(4):1180–1189. doi: 10.1172/JCI113177

Inhibition of the activation of Hageman factor (factor XII) by peripheral blood cells.

O D Ratnoff 1, M M Emanuelson 1, N P Ziats 1
PMCID: PMC442363  PMID: 3498741

Abstract

Suspensions of peripheral blood mononuclear cells (PBMC), monocytes, T or B lymphocytes, platelets or granulocytes, and cell-depleted supernatant fluids of these suspensions inhibited activation of Hageman factor (HF, Factor XII) by ellagic acid, a property not shared by erythrocytes. PBMC also inhibited HF activation by glass or sulfatides. Contaminating platelets may have contributed to inhibition by PBMC. Elaboration of agents inhibiting HF activation required metabolically active cells. The inhibitor(s) in PBMC supernates were not identified with known agents, but had properties of a nonenzymatic protein. PBMC supernates did not contain fibrinogen, nor alter the thrombin, prothrombin, or partial thromboplastin times of normal plasma, amidolysis by activated plasma thromboplastin antecedent (Factor XIa) or activated Stuart factor (Factor Xa) or esterolysis by C1 (C1 esterase); they inhibited plasmin minimally. These experiments suggest that peripheral blood cells may impede intravascular coagulation. Whether this property helps maintain the fluidity of blood is unclear.

Full text

PDF
1180

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BITTER T., MUIR H. M. A modified uronic acid carbazole reaction. Anal Biochem. 1962 Oct;4:330–334. doi: 10.1016/0003-2697(62)90095-7. [DOI] [PubMed] [Google Scholar]
  2. Chediak J., Madej-Zevin P., Ratnoff O. D., Goldsmith G. H., Jr, Everson B. Studies on a circulating anticoagulant inhibiting factor XI in a patient with congenital deficiency and carcinoma of the prostate. Br J Haematol. 1986 May;63(1):123–133. doi: 10.1111/j.1365-2141.1986.tb07502.x. [DOI] [PubMed] [Google Scholar]
  3. DULBECCO R., VOGT M. Plaque formation and isolation of pure lines with poliomyelitis viruses. J Exp Med. 1954 Feb;99(2):167–182. doi: 10.1084/jem.99.2.167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Di Scipio R. G., Hermodson M. A., Davie E. W. Activation of human factor X (Stuart factor) by a protease from Russell's viper venom. Biochemistry. 1977 Nov 29;16(24):5253–5260. doi: 10.1021/bi00643a015. [DOI] [PubMed] [Google Scholar]
  5. Donaldson V. H. Serum inhibitor of C'1-esterase in health and disease. J Lab Clin Med. 1966 Sep;68(3):369–382. [PubMed] [Google Scholar]
  6. España F., Ratnoff O. D. Activation of Hageman factor (factor XII) by sulfatides and other agents in the absence of plasma proteases. J Lab Clin Med. 1983 Jul;102(1):31–45. [PubMed] [Google Scholar]
  7. Forbes C. D., Pensky J., Ratnoff O. D. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator. J Lab Clin Med. 1970 Nov;76(5):809–815. [PubMed] [Google Scholar]
  8. Greaves M. F., Brown G. Purification of human T and B lymphocytes. J Immunol. 1974 Jan;112(1):420–423. [PubMed] [Google Scholar]
  9. Hojima Y., Cochrane C. G., Wiggins R. C., Austen K. F., Stevens R. L. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood. 1984 Jun;63(6):1453–1459. [PubMed] [Google Scholar]
  10. Kinlough-Rathbone R. L., Mustard J. F., Packham M. A., Perry D. W., Reimers H. J., Cazenave J. P. Properties of washed human platelets. Thromb Haemost. 1977 Apr 30;37(2):291–308. [PubMed] [Google Scholar]
  11. LEVY L. R., LEPOW I. H. Assay and properties of serum inhibitor of C'l-esterase. Proc Soc Exp Biol Med. 1959 Aug-Sep;101:608–611. doi: 10.3181/00379727-101-25034. [DOI] [PubMed] [Google Scholar]
  12. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  13. Lark M. W., Culp L. A. Multiple classes of heparan sulfate proteoglycans from fibroblast substratum adhesion sites. Affinity fractionation on columns of platelet factor 4, plasma fibronectin, and octyl-sepharose. J Biol Chem. 1984 Jun 10;259(11):6773–6782. [PubMed] [Google Scholar]
  14. Lederman M. M., Ratnoff O. D., Scillian J. J., Jones P. K., Schacter B. Impaired cell-mediated immunity in patients with classic hemophilia. N Engl J Med. 1983 Jan 13;308(2):79–83. doi: 10.1056/NEJM198301133080205. [DOI] [PubMed] [Google Scholar]
  15. Moore G. E., Gerner R. E., Franklin H. A. Culture of normal human leukocytes. JAMA. 1967 Feb 20;199(8):519–524. [PubMed] [Google Scholar]
  16. Moskowitz R. W., Schwartz H. J., Michel B., Ratnoff O. D., Astrup T. Generation of kinin-like agents by chondroitin sulfate, heparin, chitin sulfate, and human articular cartilage: possible pathophysiologic implications. J Lab Clin Med. 1970 Nov;76(5):790–798. [PubMed] [Google Scholar]
  17. Odegård O. R., Lie M., Abildgaard U. Antifactor Xa activity measured with amidolytic methods. Haemostasis. 1976;5(5):265–275. doi: 10.1159/000214145. [DOI] [PubMed] [Google Scholar]
  18. RATNOFF O. D., ROSENBLUM J. M. Role of Hageman factor in the initiation of clotting by glass; evidence that glass frees Hageman factor from inhibition. Am J Med. 1958 Aug;25(2):160–168. doi: 10.1016/0002-9343(58)90023-8. [DOI] [PubMed] [Google Scholar]
  19. Ratnoff O. D., Everson B., Donaldson V. H., Mitchell B. H. Purification of Hageman factor (factor XII) on columns of popcorn-agarose. Blood. 1986 Jun;67(6):1550–1553. [PubMed] [Google Scholar]
  20. Ratnoff O. D., Nossel H. L. Wasp sting anaphylaxis. Blood. 1983 Jan;61(1):132–139. [PubMed] [Google Scholar]
  21. Ratnoff O. D. Studies on the inhibition of ellagic acid-activated Hageman factor (factor XII) and Hageman factor fragments. Blood. 1981 Jan;57(1):55–58. [PubMed] [Google Scholar]
  22. Ratnoff O. D. Studies on the product of the reaction between activated Hageman factor (factor XII) and plasma thromboplastin antecedent (factor XI). J Lab Clin Med. 1972 Nov;80(5):704–710. [PubMed] [Google Scholar]
  23. Rehmus E. H., Greene B. M., Everson B. A., Ratnoff O. D. Inhibition of the activation of Hageman factor (factor XII) by complement subcomponent C1q. J Clin Invest. 1987 Aug;80(2):516–521. doi: 10.1172/JCI113100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Saito H., Ratnoff O. D., Donaldson V. H., Haney G., Pensky J. Inhibition of the adsorption of Hagemen factor (Factor XII) to glass by normal human plasma. J Lab Clin Med. 1974 Jul;84(1):62–73. [PubMed] [Google Scholar]
  25. Saito H., Ratnoff O. D., Marshall J. S., Pensky J. Partial purification of plasma thromboplastin antecedent (factor XI) and its activation by trypsin. J Clin Invest. 1973 Apr;52(4):850–861. doi: 10.1172/JCI107249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Schousboe I. beta 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood. 1985 Nov;66(5):1086–1091. [PubMed] [Google Scholar]
  27. Scully M. F., Weerasinghe K., Kakkar V. V. Inhibition of contact activation by platelet factor 4. Thromb Res. 1980 Nov 15;20(4):461–466. doi: 10.1016/0049-3848(80)90284-4. [DOI] [PubMed] [Google Scholar]
  28. Spagnuolo P. J., Ellner J. J., Hassid A., Dunn M. J. Thromboxane A2 mediates augmented polymorphonuclear leukocyte adhesiveness. J Clin Invest. 1980 Sep;66(3):406–414. doi: 10.1172/JCI109870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Steinbuch M., Audran R. The isolation of IgG from mammalian sera with the aid of caprylic acid. Arch Biochem Biophys. 1969 Nov;134(2):279–284. doi: 10.1016/0003-9861(69)90285-9. [DOI] [PubMed] [Google Scholar]
  30. Sundström C., Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer. 1976 May 15;17(5):565–577. doi: 10.1002/ijc.2910170504. [DOI] [PubMed] [Google Scholar]
  31. Weiner M. S., Bianco C., Nussenzweig V. Enhanced binding of neuraminidase-treated sheep erythrocytes to human T lymphocytes. Blood. 1973 Dec;42(6):939–946. [PubMed] [Google Scholar]
  32. Zimmerman T. S., Ratnoff O. D., Powell A. E. Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest. 1971 Jan;50(1):244–254. doi: 10.1172/JCI106480. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES